Virokine Therapeutics

Virothera is a private Cambridge, UK biotechnology company developing gene-based immune therapeutics inspired by virus immune-modulating mechanisms. Its platform uses nucleic acid delivery and proprietary constructs including VIT, CIR, and VLM to modulate chemokine pathways and immune-cell recruitment without a viral vector. The company's lead program is a preventative and therapeutic DNA vaccine candidate for recurrent herpes simplex virus type 2 infection, supported by NIH/NIAID preclinical work and progressing toward IND-enabling and pre-IND activities. Virothera is also advancing earlier oncology and autoimmune applications, including programs for triple-negative breast cancer and rheumatoid arthritis. The company appears to have rebranded from Virokine Therapeutics to Virothera while remaining an active private biotech.